Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Synovitis, Pigmented Villonodular 1Pancreatic Neoplasms 1Diabetes Mellitus, Type 2 1Adult Solid Neoplasm 1

Interventions

AZD 6244 2ARQ 197 2veliparib 1temsirolimus 1sargramostim 1pegfilgrastim 1cixutumumab 1belinostat 1Topotecan 1Tolbutamide 1Sunitinib 1Sirolimus 1Rifampin 1Phantoms, Imaging 1Omeprazole 1Midazolam 1Magnetic Resonance Spectroscopy 1Ketoconazole 1Isotretinoin 1Introns 1Interferon alpha-2 1Hydroxychloroquine 1Gemcitabine 1Dextromethorphan 1Colony-Stimulating Factors 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adult Solid Neoplasm × Tolbutamide × Clear all
NCT01218620 2014-12-23

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡